Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Phase 2/3 OV company Genelux trades at US$35.00
View:
Post by Noteable on Jun 18, 2023 11:54am

Phase 2/3 OV company Genelux trades at US$35.00

https://en.wikipedia.org/wiki/Genelux_Corporation

https://clinicaltrials.gov/ct2/show/NCT05281471

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer.
Comment by Noteable on Jun 18, 2023 12:17pm
In Genelux's Phase 2 clinical trial of 27 heavily pretreated patients with platinum-resistant or -refractory ovarian cancer (PRROC [platinum-resistant (n=14) or platinum-refractory (n=13)] and median 4 prior lines of therapy, Olvi-Vec followed by platinum-based chemotherapy ± bevacizumab as immunochemotherapy demonstrated objective response rate (ORR) of 54% and a median ...more  
Comment by Noteable on Jun 18, 2023 12:29pm
Results from ONCY's Bracelet-1 Phase 2 study in heavily pre-treated metastatic breast cancer patients treated with the single agent pelareorep + chemotherapy showed: - Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy - 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3%  ...more  
Comment by Noteable on Jun 18, 2023 2:39pm
Ask FUD if he's buying GNLX.
Comment by fox7mf on Jun 21, 2023 1:14pm
It would appear that Genelux has been a public company for all of 6 months...c'mon Coffey, make Oncy's 25th year its last. Sell now!!!!
Comment by westcoast1000 on Jun 21, 2023 3:30pm
Yes, Genelux is a competitor and an interesting comparison. They are active in different indications than ONCY but parallels are striking. Note they had an IPO six months ago at $6 US. They have about 24 mil shares out. We are a bit over $2 US and have 63 mil shares out. The opportunity offered by Genelux at its IPO is comparable to the equity available in buying shares in ONCY at the current ...more  
Comment by westcoast1000 on Jun 21, 2023 5:23pm
It is possible that the ongoing interest and price increase in Genelux is spilling over onto ONCY.
Comment by Lesalpes29 on Jun 21, 2023 9:13pm
Probably something else. Volume is good since monday of last week. Something good is coming.
Comment by Noteable on Jun 20, 2023 11:28am
Trading at US$36.50 today.
Comment by Noteable on Jun 20, 2023 1:12pm
Now trading at US$38.00
Comment by fox7mf on Jun 20, 2023 1:23pm
Wow. $37.8 usd...MC could take some lessons in shareholder value creation from these guys. Where, when, who & how much Matty?
Comment by Noteable on Jun 20, 2023 1:52pm
Instead those who are prone to criticisim fail to see the inherent value in ONCY as witnessed by this example.
Comment by Noteable on Jun 20, 2023 1:55pm
However their true critical character continues to shines through.
Comment by Noteable on Jun 20, 2023 4:25pm
In every post they make, they keep proving out their true critical nature of their negative character.
Comment by Noteable on Jun 21, 2023 9:53am
Trading today at a high of US$40.00 per share - June 21, 2023
Comment by inthno on Jun 21, 2023 10:36am
Thanks Note for the genelux information. I went to their website and they are actively enrolling in a phase 3 program....This helps show the potential for onc but also is another virus which could be considered direct competition. Their virus basically does exactly what our virus is supposed to do and they are moving ahead quickly at this point. Olvi-Vec, our lead product candidate, is a modified ...more  
Comment by fox7mf on Jun 20, 2023 2:01pm
I think many of us investors feel a little short changed at this point, particularly in light of how Matt pumped the next '6-9 months' back in November. The lack of positive news and movement brings on insecurities and angst. 
Comment by Lesalpes29 on Jun 20, 2023 3:01pm
I think you right... Matt was very confident. Now he has to deliver. 
Comment by Lesalpes29 on Jun 20, 2023 1:52pm
Fox it's probably because Matt has almost zero credibility! The rest of the board need to help him with that! 
Comment by fox7mf on Jun 20, 2023 3:27pm
On another, we continue to see fairly impressive and above average volume in the US. I don't know if this suggests slow accumulation, but maybe. 
Comment by Lesalpes29 on Jun 20, 2023 3:39pm
Exactly Fox... slow and a more heavy accumulation? Could be.
Comment by westcoast1000 on Jun 20, 2023 3:21pm
Noteable, Thanks for pointing out Genelux. I was not aware of that company.  This is a sincere question. Could you provide a quick statement on how that company differs from and/or is similar to ONCY? What do you think their investors see there to maintain their share price, while our share price and market cap is where it is? Are they ahead of us? Competitors of ours?  In general ...more  
Comment by westcoast1000 on Jun 20, 2023 3:22pm
 correction:  of...Noteable (delete any)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities